Franciscan Health System. Aug P u b l i s h e d f o r o u r M e d i c a l S t a f f

Size: px
Start display at page:

Download "Franciscan Health System. Aug. 2011. P u b l i s h e d f o r o u r M e d i c a l S t a f f"

Transcription

1 Connections P u b l i s h e d f o r o u r M e d i c a l S t a f f Franciscan Health System Aug St. Elizabeth Hospital St. Anthony Hospital Franciscan Medical Group I n s i d e CMS introducing new quality measures News Notes Pharmacy News Medical staff and CME calendar Medical staff newsletter readership survey starts later this month Franciscan Health System values the opinions of its medical staff members. Starting this month, Franciscan will ask its medical staff to participate in a brief online survey regarding the usefulness of this monthly newsletter and how it could be improved. So watch your for the link to the questionnaire and we look forward to your responses. Thank you. Emerging blood thinners inspire question: Is newer better? By Rebecca Vigil, RN Transfusion-Free & Program Dabigatran etexilate mesylate (Pradaxa ) is a direct thrombin inhibitor that is FDA-approved to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation. Pradaxa has become a popular alternative to warfarin therapy because it does not require laboratory monitoring, dose adjustments or diet modification. While Pradaxa provides excellent anti-coagulation for the approved indication, there are risks. For example, there is no antidote in the event of accidental overdose or hemorrhagic complications. Recommended treatment in these situations is to discontinue Pradaxa, investigate the source of bleeding, and maintain adequate diuresis (Pradaxa is primarily excreted in urine). There are also suggestions that 1) dialyzing the patient over 2-3 hours, 2) surgical hemostasis, 3) transfusion of fresh frozen plasma (FFP) or red blood cells, or 4) administering activated prothrombin complex concentrates (PCC), recombinant Factor VIIa or coagulation factors II, IX or X, may prove beneficial. The usefulness of these treatment regimens has not been established in clinical settings. Dabigatran is on the Franciscan formulary for its FDA-indicated use. On July 1, 2011 the FDA approved the oral anticoagulant rivaroxaban (Xarelto ) to reduce the risk of blood clots, deep vein thrombosis and pulmonary embolism following knee or hip replacement surgery. Xarelto inhibits coagulation Factor Xa and has a halflife of 5-9 days. There is no known While the medical community has welcomed new medications, their use is not without risks. reversal agent for Xarelto in the event of a hemorrhagic complication and, due to the high plasma protein binding, rivaroxaban is not expected to be dialyzable. Administration of blood products or factor concentrates may be helpful but have not been studied. Rivaroxaban will be reviewed by the PT&T Committee in September or October Prasugrel (Effient ) is a P2Y12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients Continued on page 2 Connections August 2011 Advanced. Trusted Care. 1

2 Medical staff Leadership FHS Medical Executive Committee Kim L. Moore, MD Medical Staff President Charles Leusner, MD Vice President-elect, SFH Navdeep S. Rai, MD Member-at-Large, SFH Kevin E. Braun, MD Vice President, SCH Brian A. Folz, MD Member-at-Large, SAH Byron L. Hutchinson, DPM Member-at-Large, SFH William B. Cammarano III, MD Vice President-elect, SJMC Peter R. Kesling, MD Member-at-Large, SAH Ulrich Birlenbach, MD Member-at-Large, SCH FHS Credentials Committee Norman H. Burns, MD David S. Cho, MD Richard K. Gould, MD, Chair Youl Choi, MD Brian Folz, MD Section Chiefs Gail C. Venuto, MD Keith E. Demirjian, MD Peggy Dunlop, CNM Midwifery Eugene S. Cho, MD Tejinderpal Singh, MD G. Gordon Benjamin, MD Diagnostic Imaging Section Chiefs Jeffrey M. Cortazzo, MD W. Mark Hassig, MD Linda M. Petter, DO Kevin J. Ward, MD Michael S. Davidov, MD Section Chiefs David R. Kennel, MD David R. Munoz, MD Youl Choi, MD GYN Mark S. Yuhasz, MD Radiology Linda D. Burkhardt, MD St. Anthony Hospital Section Chiefs Gary R. Pingrey, DO Linda D. Burkhardt, MD Raed N. Fahmy, MD Thomas J. Minter, MD Cynthia M. Mosbrucker, MD Charles M. Piatok, MD GYN Jason W. Allen, MD Robert A. Yancey, MD Radiology St. Elizabeth Hospital Medical Staff Officers Jude Verzosa, MD Medical Staff President Allen H. Yu, MD Vice President-elect, SCH Wendy Weeks, MD Member-at-Large, SJMC Neville A. Lewis, MD Member-at-Large, SJMC Robert T. Middleton, MD Vice President, SFH Thomas J. Minter, MD Vice President, SAH Daniel G. Nehls, MD Vice President, SJMC Donald L. George, MD Vice President-elect, SAH Micheal W. Vier, MD Member-at-Large, SCH W. Mark Hassig, MD Paul W. Hildebrand, MD Bruce Wilson, MD H. James Yamashita, MD Mark Yuhasz, MD William B. Cammarano III, MD Allister Stone, DO J. Dale Howard, MD Mental Health Linda D. Burkhardt, MD Martin V. Cieri, MD Pediatrics Charles Leusner, MD Diagnostic Imaging Andrew M. Elizaga, MD Mohinder S. Badyal, MD Pediatrics Linda D. Burkhardt, MD Kim L. Moore, MD Keith A. Weissinger, MD Pediatrics Charles M. Piatok, MD Steven G. Duras, MD Steve Atkinson, MD Vice President Franciscan Health System is guided by the Ethical and Religious Directives for Catholic Health Care Services. Coming in January 2012: New CMS quality core measures Beginning Jan. 1, 2012, two new CMS quality core measures will be added and Franciscan Health System will report its results for both. These will be Imm-1: Pneumococcal Immunization and Imm- 2: Influenza Immunization. The new global measures with retire the current pneumonia measures, PN- 2: Pneumococcal Vaccination and PN-7: Influenza Vaccination. The addition of the two quality measures will expand the inpatient population targeted for screening and vaccinating. Pneumococcal Immunization Measure The patient numerator captures two activities screening and intervention of vaccine administration, when indicated. The measure includes inpatients 65 years of age and older; 9-64 years of age with a principal diagnosis of asthma; and patients 6-64 years of age with a principal or other diagnosis of diabetes, nephritic syndrome, ESRD, HF, COPD, HIV or asplenia. Influenza Immunization Measure Just as the pneumococcal vaccine measure does, the patient numerator specifies two activities, blood thinners, from page 1 with acute coronary syndrome (ACS) who are managed with percutaneous coronary intervention. Clopidogrel bisulfate (Plavix ) is another P2Y12 platelet inhibitor indicated for ACS, recent myocardial infarction/stroke or established peripheral arterial disease. Quality & Safety Club100 Quick Tip screening and intervention of vaccine administration, when indicated. The measure includes inpatients age 6 months and older, discharged during September through March, with any diagnosis. The new global pneumococcal and influenza immunization measures require a revision of the Nurse Initiated Vaccine Assessment Order (NIVAO) form and guidelines. Updates are currently in the process and will be completed by Sept. 1, 2011 in order to prepare clinical staff and providers for measure reporting starting in January For more information about the quality measures or to request a free copy of the Franciscan Quality Indicators booklet, please contact Whende Martin, RN, Franciscan Clinical Effectiveness, or by at Quick Tip is published in each edition of this newsletter to help Franciscan medical staff members achieve 100-percent compliance with CMS clinical quality indicators for acute myocardial infarction, pneumonia, heart failure and the Surgical Care Improvement Project (SCIP). Both inhibit platelet aggregation for the lifetime of the platelet (7-10 days), thus withholding a dose will not be useful in managing a bleeding event nor mitigating bleeding risk associated with an invasive procedure. For both drugs, platelet transfusion at least 2-4 hours after the Continued on page 5 2 Advanced. Trusted Care. August 2011 Connections

3 Blackwell accepts leadership post in Pennsylvania Fran Blackwell, vice president for outpatient services for the Franciscan Health System, has accepted the position of senior vice president for ambulatory services at Lehigh Valley Health Network in Pennsylvania. This change will afford her and her husband the opportunity to relocate close to their families. Her last day with Franciscan is Aug. 26, Since joining Franciscan in 2005, she has advanced the organization s hospice and palliative care programs, diagnostic imaging services, rehabilitation therapies, sleep therapy programs, occupational health, cardiopulmonary, wound care, hyperbaric, and neuroscience services. She also helped lead Franciscan's collaboration with TRA Medical Imaging and the MultiCare Health System to establish the Carol Milgard Breast Center in Tacoma. Her successor has not yet been announced. St. Anthony president will lead Colorado hospital Carole Peet, president of St. Anthony Hospital in Gig Harbor, has accepted the position of president and chief executive officer at St. News notes F. Blackwell C. Peet Anthony North Hospital, a 196-bed facility in the Denver suburb of Westminster. This move will not only allow Peet to be close to her son s family, including her grandchildren, but allow her to remain associated with the ministry of Catholic Health Initiatives (CHI). The Colorado hospital is part of Centura Health and, like Franciscan Health System, is affiliated with CHI. Her last day with Franciscan will be Sept. 2, Peet, who helped to open the Gig Harbor hospital in 2009, is also the service line executive for Franciscan's nephrology and mental health services. Her successor will be announced at a later date. St. Elizabeth president announces plan to retire St. Elizabeth Hospital President Dennis Popp, who has successfully led efforts to expand medical services on the Enumclaw Plateau for 25 years, has announced his intention to begin transitioning toward retirement. He has not set a specific date to retire, giving the Franciscan Health System sufficient time to recruit his successor as president of Enumclaw s only hospital. Until a new president for St. Elizabeth is found, it s business-as-usual, said Franciscan Chief Operating Officer Cliff Robertson, MD. D. Popp I would not trade the past 25 years for anything, said Popp, who received the 2008 Joe Hopkins Memorial Award for leadership from the Washington State Hospital Association. Northwest Vascular Center expands vascular ultrasound Northwest Vascular Center-Enumclaw, a part of the Franciscan Medical Group, now provides outpatient vascular ultrasound services for St. Elizabeth Hospital and medical group patients on the Plateau. Northwest Vascular Center-Enumclaw also provides inpatient and emergency vascular ultrasound services at St. Elizabeth. For more information, contact clinic Manager Marilyne Tweit at or by FHShealth.org. TRA provides after-hours imaging studies at Enumclaw TRA Medical Imaging now provides after-hours interpretations of urgent imaging studies for St. Elizabeth Hospital in Enumclaw. The change, which took effect July 14, is expected to improve turnaround time for reports. Until now, the after-hours support was provided by an out-of-state call service. David Rice, MD, and Lon Hayne, MD, are the radiologists at St. Elizabeth. For more information, contact Rich Rosser, diagnostic imaging manager, at or by at Medical office space open on St. Joseph campus Seeking medical space to lease on the campus? An office (2,176 square feet) is available in Suite 201 of the St. Joseph Medical Pavilion, 1802 S. Yakima Ave. Call Franciscan Property Management: Franciscan Foundation awards 33 scholarships to employees The Franciscan Foundation recently awarded scholarships to 33 Franciscan Health System employees who are pursuing undergraduate or graduate degrees or certificates in health care and other career-related subjects. The scholarships totaled $64,400. Since 1996, the Foundation has given 314 scholarships to Franciscan staff totaling $497,300. All scholarships are funded through charitable gifts to the Foundation. Connections August 2011 Advanced. Trusted Care. 3

4 P h a r m a c y N e w s Contact: Franciscan Pharmaceutical Services, Dronedarone (Multaq ): two-fold increases in stroke and Increased risk of death and cardiovascular adverse events The FDA is reviewing data from a clinical trial evaluating the effects of the antiarrhythmic drug dronedarone (Multaq ) in patients with permanent atrial fibrillation. The study was stopped early after the data-monitoring committee found a two-fold increase in death, as well as hospitalization for heart failure, in patients receiving Multaq compared to those taking a placebo. Multaq is approved for reducing the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be Table 1: PALLAS study events as of June 30, 2011 Multaq N=1572 n (%) CV death, myocardial infarction, 32 (2) stroke, systemic embolism* Death, unplanned CV 118 (7.5) hospitalization* Death 16 (1) Myocardial infarction 3 (0.2) Stroke 17 (1.1) Heart failure hospitalization 34 (2.2) Placebo N=1577 n (%) 14 (0.9) 81 (5.1) Hazard Ratio p-value (0.4) 3 (0.2) 7 (0.4) 15 (1) *Co-primary endpoints References Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009 Feb 12;360(7): Source: SDI, Vector One : National (VONA) and Total Patient Tracker (TPT). July 2009-June Extracted Weight (kg) 15 kg or less 16 kg thru 23 kg 24 kg thru 40 kg 41 kg or more Weight (lbs) 33 lbs or less 34 lbs thru 51 lbs 52 lbs thru 88 lbs 89 lbs or more Treatment dosing for 5 days 30 mg twice 45 mg twice 60 mg twice 75 mg twice Table 2: New Tamiflu Dosing Chart Prophylaxis dosing for 10 days 30 mg once 45 mg once 60 mg once 75 mg once Volume of oral suspension (6 mg/ml) for each dose* 5 ml 7.5 ml 10 ml 12.5 ml cardioverted. From approval in July 2009 through June 2011, approximately 1 million Multaq prescriptions were dispensed by outpatient retail pharmacies in the U.S. Approximately 241,000 individuals received Multaq prescriptions. The Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy Study (PALLAS), sponsored by Sanofi Aventis, was being conducted to assess the potential clinical benefit of Multaq in patients over 65 with permanent atrial fibrillation in the reduction of: Major cardiovascular (CV) events Unplanned cardiovascular hospitalization, or death from any cause. A critical question is whether and how unfavorable results of the PALLAS study, obtained in patients with permanent atrial fibrillation, apply to patients who use Multaq for approved indications (i.e., nonpermanent atrial fibrillation, also known as paroxysmal or persistent atrial fibrillation). Number of bottles of for oral suspension to dispense 1 bottle 2 bottles 2 bottles 3 bottles Number of capsules and strength to dispense 10 capsules 30 mg 10 capsules 45 mg 20 capsules 30 mg 10 capsules 75 mg *A 10 ml oral dosing dispenser is provided with the oral suspension. In the event that the dispenser provided is lost or damaged, another dosing dispenser may be used to deliver the volume. Delivery of this Tamiflu oral suspension dose requires administering 10 ml followed by another 2.5 ml. References U.S. National Library of. National Institutes of Health. Drug Monograph-Oseltamivir. Available at meds/a html. Accessed April 15, At this time, patients taking Multaq should talk to their health care provider about whether they should continue to use the product for non-permanent atrial fibrillation. Health care professionals should not prescribe Multaq to patients with permanent atrial fibrillation. FDA is evaluating whether and how the preliminary results of the PALLAS study apply to patients taking Multaq for paroxysmal or persistent atrial fibrillation or atrial flutter. PALLAS results (Table 1) are considered preliminary since the data have not undergone qualityassurance procedures nor been completely adjudicated. 2 Changes to oseltamivir phosphate (Tamiflu ) for oral suspension The FDA has informed the public and health care practitioners of important product safety changes to the influenza drug oseltamivir (Tamiflu ) for oral suspension. These changes will reduce the prescribing and dosing confusion that can lead to medication errors. FDA has worked with the manufacturer, Genentech, to make these changes. Tamiflu is used to treat some types of flu in adults and children (older than 1 year) who have had symptoms for no longer than two days. It also is used to prevent some types of flu in adults and children (older than 1 year) when they have spent time with someone who has the flu or when there is a flu outbreak. Changes to Tamiflu oral suspension and the product label include: Changing the concentration of from 12 mg/ml to 6 mg/ml. The Continued on page 5 4 Advanced. Trusted Care. August 2011 Connections

5 Franciscan Medical Staff Additions December 2010 June 2011 (Listed by name, specialty, primary hospital) Adam Balkany, DO Faye Buloan-Siek, MD Palliative Khalil Carter, MD Jay Casino, MD St. Anthony Hospital Youssef Chami, MD Cardiology Meghana Doreswami, MD Neurology Boguslawa Grazyna, MD Patrick Fisher, MD Cardiovascular Disease Marilyn Gage, MD Prashanthi Ganathi, MD Rebecca Houseman, MD Muhammad Husainy, DO Dana Hunter, MD Ghalib Husseini, MD Orthopedic Colin Iosso, MD Neurology Barbara Lazio, MD Neurological Sarah Maitre, MD Family Margaret McKee, MD Pulmonary Disease Hiroki Mitsuyama, MD Radiation Oncology Daniel Moore, MD Gregory Moore, MD Alex Moreano, MD ENT In Kwon Park, MD Grazyna Perczak-Dudkowska, MD Nasir Rashid, MD Neonatology Linda Rimkunos, MD Richard Rybarczyk, MD Eve Shank, MD ENT Matthew Shepherd, MD St. Anthony Hospital Amanda Steen, MD Physical & Rehabilitation Bobby Stevens, DO General Catherine Thompson, MD Nephrology Kenneth Tyson, DO Gynecology Richard Urbon, MD David Vance, MD Urology Michael Vaughn, MD Nephrology Umesh Chitaley, MD Wei Guo, DDS Oral/Maxillofacial Gregory Lamberton, MD Urology Jennifer Muldoon, MD Suraj Singh, MD Radiation Oncology St. Anthony Hospital Troy Wadsworth, MD Jasmine Daniels, MD Ali Habib, MD Neurology Maggie Likes, MD Pediatric Cardiology Keven Nevil, MD Gynecology Stirling Smith, DO Neil Wang, DO Lakshmi Datla, MD Sabrina Hart, MD Family Gabriela Loperena Oropeza, MD Endocrinology Kurt Norman, MD Kenneth Son, MD Xinda Wang, MD Helene DeHaan, ARNP Family Nurse Practitioner Scott Harriage, MD Gynecology Emily Luerssen, MD R. Steven Norton, MD Trauma Douglas Sorenson, MD ENT Sarah Waverveld, DPM Podiatry Trevor Dennie, MD Susanne Hopkins, MD Carlos Justiniano, MD Trauma Gabriela Oropeza, MD Endocrinology Patricia Spitale, MD Neonatology Marjan Zarghami, MD Pharmacy News, from page 4 lower concentration is less likely to become frothy when shaken, which helps ensure an accurate measurement. The 12 mg/ml concentration will not be marketed after current supplies are used. Changing measurements of the oral-dosing device from milligrams (mg = weight) to milliliters (ml = volume). Changing the dosing table to include a column for the volume (ml) based on the new 6 mg/ml concentration (see Table 2). Revising container labels and carton packaging Revising compounding instructions for pharmacies to prepare a 6 mg/ml oral suspension from Tamiflu capsules in an emergency situation only if commercially manufactured Tamiflu for oral suspension is unavailable. Genentech planned to begin distribution of the new 6 mg/ml product in July The company has instituted a voluntary Take Back Program for wholesale buyers, distributors and pharmacies to remove the 12 mg/ml product from the marketplace. emerging blood thinners, from page 2 last dose may restore clotting ability. While the medical community has welcomed these new medications to the market and current practice employs them regularly, it is clear that their use is not without risks and these must be assessed on a case-by case basis. At the Franciscan Health System, we see about 4,500 patients a year who refuse transfusion of allogeneic blood products due to personal beliefs. For them, the use of fresh frozen plasma or red blood cell transfusions is not an option. Moreover, PCC, cryoprecipitate or other coagulation factors may or may not be acceptable to them. Therefore, these anticoagulants may be contraindicated in this patient population as the risks could outweigh the benefits. *Sources for this article included prescribing information for Pradaxa, Xarelto, Plavix and Effient. Connections August 2011 Advanced. Trusted Care. 5

6 Medical Staff Calendar August 1 Credentials Committee, SJMC, 7 a.m., Portview Conference Room Journal Club, SCH, cancelled, no lunch Grand Rounds, SEH, 5:30 p.m. 7 p.m. Clinical Cardiac MRI: Established & Emerging Applications, Jeffrey Rose, MD, and Negar Knowles, MD, Rainier Room. RSVP to Pelvic Floor Disorder Conference (not Category I), SJMC, 6 8 p.m., Lagerquist A&B 2 Neuro/Gamma Knife Conference, SJMC, 7 8 a.m., Neuro/Gamma Knife Conference Room CME Committee, SJMC, cancelled Chief Medical Officer Advisory Council, SJMC, 5:45 p.m., Lagerquist A&B 3 Tumor Board, SJMC, 7 8 a.m., Dining Rooms 1&2 4 Pierce County Breast Conference, 10 Tumor Board, SJMC, 7 8 a.m., Dining Rooms 1 & 2 11 Pierce County Breast Conference, Breast Care Conference, SFH, 12 p.m., Grand Rounds, SJMC, cancelled for FHS Medical Executive Committee, SJMC, 5:45 p.m., Lagerquist A&B 12 Grand Rounds, SFH, cancelled for SAH Medical Staff Operating Committee, SAH, 7 a.m., Smalling Conference Room 15 Journal Club, SCH, cancelled, no lunch 16 Neuro/Gamma Knife Conference, SJMC, 7 8 a.m., Neuro/Gamma Knife Conference Room Franciscan Health System Connections 1717 South J Street, Tacoma Neurological Sciences Grand Rounds (not Category I), SJMC, 6 p.m., Dining Rooms 1 & 2 17 Tumor Board, SJMC, 7 8 a.m., Lagerquist A 18 Pierce County Breast Conference, 19 Tumor Board, SFH, 12 p.m., 22 Journal Club, SCH, cancelled, no lunch 23 Medical Research Evaluation Committee, SJMC, 12 p.m., Lagerquist C 24 Tumor Board, SAH, 7 8 a.m., Larson Conference Room Tumor Board, SJMC, 7 8 a.m., Lagerquist A SCH Medical Staff Operating Committee, SCH, 6 p.m., Classrooms A&B 25 Performance Quality Leadership Group, cancelled Pierce County Breast Conference, Breast Care Conference, SFH, 12 p.m., Grand Rounds, SJMC, cancelled for 26 GU Conference, SFH, 12 p.m., Grand Rounds, SFH, cancelled for 29 Credentials Committee, SJMC, 7 a.m., Portview Conference Room (rescheduled from Sept. 5) Journal Club, SCH, cancelled, no lunch 31 Tumor Board, SJMC, 7 8 a.m., Dining Rooms 1&2 Legend: SJMC=; SFH=; SCH=; SAH=St. Anthony Hospital; SEH=St. Elizabeth Hospital; MOB=Medical Office Building; Carol Milgard Breast Center is at 4525 S. 19th St., Tacoma N o n p r o f i t O r g. U. S. P o s t a g e Pa i d Ta c o m a, WA P e r m i t N o Please note: Journal Club and lunch have been permanently cancelled for the 2nd Monday of each month. Printed on Recycled Paper Advanced. Trusted Care. 6 August 2011 Connections

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment

More information

DVT/PE Management with Rivaroxaban (Xarelto)

DVT/PE Management with Rivaroxaban (Xarelto) DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular

More information

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about

More information

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November

More information

ABOUT XARELTO CLINICAL STUDIES

ABOUT XARELTO CLINICAL STUDIES ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the

More information

More information for patients and caregivers can be accessed at http://www.xarelto-us.com/.

More information for patients and caregivers can be accessed at http://www.xarelto-us.com/. Janssen Research & Development Submits Application to U.S. FDA for XARELTO (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome RARITAN, DECEMBER 29, 2011 -

More information

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of

More information

Critical Bleeding Reversal Protocol

Critical Bleeding Reversal Protocol Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy

More information

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics

More information

The Role of the Newer Anticoagulants

The Role of the Newer Anticoagulants The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention

More information

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,

More information

Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions

Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions What is atrial fibrillation?...2 What are dabigatran, rivaroxaban and apixaban and what are they used for?...2

More information

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Duration of Dual Antiplatelet Therapy After Coronary Stenting Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are

More information

LAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options

LAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow

More information

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime

More information

East Kent Prescribing Group

East Kent Prescribing Group East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal

More information

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy ~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:

More information

The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences

The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences Center September 25, 2015 Question: With which of the

More information

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation PATIENT EDUCATION GUIDE What is atrial fibrillation? Atrial fibrillation

More information

The author has no disclosures

The author has no disclosures Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author

More information

News Release. Media contacts: Ernie Knewitz Tel: 908.927.2953 Mobile: 917.697.2318 eknewitz@its.jnj.com

News Release. Media contacts: Ernie Knewitz Tel: 908.927.2953 Mobile: 917.697.2318 eknewitz@its.jnj.com News Release Media contacts: Ernie Knewitz Tel: 908.927.2953 Mobile: 917.697.2318 eknewitz@its.jnj.com Shaun Mickus Phone: 908.927.2416 Mobile: 973.476.7144 smickus@its.jnj.com Investor contacts: Stan

More information

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach. Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight

More information

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as

More information

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia

More information

Comparison between New Oral Anticoagulants and Warfarin

Comparison between New Oral Anticoagulants and Warfarin Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several

More information

Dabigatran (Pradaxa) Guidelines

Dabigatran (Pradaxa) Guidelines Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without

More information

Antiplatelet and Antithrombotics From clinical trials to guidelines

Antiplatelet and Antithrombotics From clinical trials to guidelines Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories

More information

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness

More information

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in

More information

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin. To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION

STROKE PREVENTION IN ATRIAL FIBRILLATION STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients

More information

Patient frequently asked questions

Patient frequently asked questions Patient frequently asked questions What is atrial fibrillation?...2 What are dabigatran and rivaroxaban and what are they used for?...2 Which is better, dabigatran or rivaroxaban?...2 For patients with

More information

Rivaroxaban (Xarelto ) by

Rivaroxaban (Xarelto ) by Essentia Health Med Moment Short Video Tune-Up A brief overview of a new medication, or important new medication information Rivaroxaban (Xarelto ) by Richard Mullvain RPH BCPS (AQC) Current - August 2011

More information

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban

More information

New Anticoagulants: What to Use What to Avoid

New Anticoagulants: What to Use What to Avoid New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA

More information

EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012

EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012 EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF Recorded Webcast Update for Analysts and Investors March 26, 2012 1 Webcast Presentation Agenda EINSTEIN PE Clinical Trial

More information

Hot Line Session at European Society of Cardiology (ESC) Congress 2014:

Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily

More information

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients

More information

Optimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015

Optimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015 Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen

More information

Thrombosis and Hemostasis

Thrombosis and Hemostasis Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND: STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention

More information

Outpatient Anticoagulation Treatment Packet

Outpatient Anticoagulation Treatment Packet Emergency / Pharmacy Services Outpatient Anticoagulation Treatment Packet Check when complete (If indicated): Primary Care Provider Follow Referral to Franciscan Transitional Clinic (if no primary care

More information

Dorset Cardiac Centre

Dorset Cardiac Centre P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February

More information

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012 New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk

More information

Cardiovascular Disease

Cardiovascular Disease Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage

More information

FDA Approved Oral Anticoagulants

FDA Approved Oral Anticoagulants FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic

More information

HCIM ICD-10 Training Online Course Catalog August 2015

HCIM ICD-10 Training Online Course Catalog August 2015 HCIM ICD-10 Training Online Course Catalog August 2015 Course/Content Duration Quiz Duration CME Credits Assessments: Assessment: Provider - Baseline - E/M Emergency Department 45 5/1/2015 Assessment:

More information

Title of Guideline. Thrombosis Pharmacist)

Title of Guideline. Thrombosis Pharmacist) Title of Guideline Contact Name and Job Title (author) Guideline for patients receiving Rivaroxaban (Xarelto ) requiring Emergency Surgery or treatment for Haemorrhage Julian Holmes (Haemostasis and Thrombosis

More information

GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY

GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY BLOOD CONSERVATION STRATEGIES IN CARDIAC SURGERY: MORE IS BETTER GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY DIMITRIOS V. AVGERINOS MD, PhD, FACS, FACC Department of Cardiac Surgery,

More information

Cardiology Update 2014

Cardiology Update 2014 Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The

More information

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban

More information

Introduction. Background to this event. Raising awareness 09/11/2015

Introduction. Background to this event. Raising awareness 09/11/2015 Introduction Primary Care Medicines Governance HSCB Background to this event New class of medicines Availability of training Increasing volume of prescriptions Reports of medication incidents Raising awareness

More information

Anticoagulation Therapy Update

Anticoagulation Therapy Update Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2

More information

indications November 2 nd, 2012 Dalhousie University

indications November 2 nd, 2012 Dalhousie University + New oral anticoagulants: A review of current indications November 2 nd, 2012 Dr. Sudeep Shivakumar, Hematology Dalhousie University + Objectives es To review indications for anticoagulation To discuss

More information

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment

More information

The speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.

The speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products. Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives

More information

Time of Offset of Action The Trial

Time of Offset of Action The Trial New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About

More information

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 06/06/2012 Review Date 06/06/2014 Version 1.1 EQIA Yes /

More information

New Oral Anticoagulant (Rivaroxaban [Xarelto])

New Oral Anticoagulant (Rivaroxaban [Xarelto]) TABLE OF CONTENTS New Oral Anticoagulant (Rivaroxaban [Xarelto]) 1-2 New Antiplatelet (Ticagrelor [Brilinta]) 2-3 Update on Dabigatran (Pradaxa) Safety and Use at UIMCC 3-4 What Methods are Available for

More information

Disclosures. Objective (NRHS) Self Assessment #2

Disclosures. Objective (NRHS) Self Assessment #2 Development and Implementation of a Protocol for Reversing the Effects of Anticoagulants for Use in a Community Hospital Samantha Sepulveda, Pharm.D. PGY1 Pharmacy Resident Norman Regional Health System

More information

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Late-Breaking Science at ESC Congress 2015: New Real-World Evidence Reaffirms

More information

NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION

NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION Version 3 August 2014 NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION Dorset CCG commissions the use of newer oral anti-coagulants in accordance

More information

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7

More information

NWMIC Medicines FAQ. New oral anticoagulants (NOACs) and management of dental patients - Dabigatran, rivaroxaban and apixaban.

NWMIC Medicines FAQ. New oral anticoagulants (NOACs) and management of dental patients - Dabigatran, rivaroxaban and apixaban. NWMIC Medicines FAQ New oral anticoagulants (NOACs) and management of dental patients - Date prepared: May 2013, updated November 2013 Summary In primary care; Consider liaising with the local hospital

More information

1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF

1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology

More information

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38 Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac

More information

The management of cerebral hemorrhagic complications during anticoagulant therapy

The management of cerebral hemorrhagic complications during anticoagulant therapy The management of cerebral hemorrhagic complications during anticoagulant therapy Maurizio Paciaroni Stroke Unit Division of Cardiovascular Medicine University of Perugia - Italy Perugia Stroke Registry

More information

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory

More information

Xarelto (Rivaroxaban)

Xarelto (Rivaroxaban) Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,

More information

Franciscan Health System. Oct. 2011. P u b l i s h e d f o r o u r M e d i c a l S t a f f

Franciscan Health System. Oct. 2011. P u b l i s h e d f o r o u r M e d i c a l S t a f f Connections P u b l i s h e d f o r o u r M e d i c a l S t a f f Franciscan Health System Oct. 2011 St. Francis Hospital St. Clare Hospital St. Elizabeth Hospital St. Anthony Hospital Franciscan Medical

More information

Blood products and pharmaceutical emergencies

Blood products and pharmaceutical emergencies Blood products and pharmaceutical emergencies Kasey L. Bucher PharmD, BCPS Clinical Specialist, Emergency Medicine Mercy Health Saint Mary s September 12, 2013 Disclosures None significancemagazine.com

More information

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012

More information

Anticoagulation before and after cardioversion; which and for how long

Anticoagulation before and after cardioversion; which and for how long Anticoagulation before and after cardioversion; which and for how long Sameh Samir, MD Cardiovascular medicine dept. Tanta faculty of medicine Atrial fibrillation goals of management Identify and treat

More information

Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery

Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients

More information

Analytical Specifications RIVAROXABAN

Analytical Specifications RIVAROXABAN Page 1 of 9 ANALYTE NAME AND STRUCTURE - RIVAROXABAN SYNONYMS Xarelto CATEGORY Anticoagulant TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND Xarelto (rivaroxaban) is an orally

More information

Newer Anticoagulants and Newer Diabetic Drug Classes. Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013

Newer Anticoagulants and Newer Diabetic Drug Classes. Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013 Newer Anticoagulants and Newer Diabetic Drug Classes Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013 Apixaban Newer Anticoagulants Dabigatran etexilate Rivaroxaban

More information

Reversing the New Anticoagulants

Reversing the New Anticoagulants Reversing the New Anticoagulants Disclosure Susan C. Lambe, MD Assistant Clinical Professor Department of Emergency Medicine University of California, San Francisco Roadmap for today 1 Roadmap for today

More information

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,

More information

THE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS

THE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS THE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS Ingo Ahrens, Christoph Bode Cardiology and Angiology I, Heart Center Freiburg University, Freiburg,

More information

NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS

NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016

More information

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban

More information

Prostate Assessment Pathway Prostate Biopsy Alerts

Prostate Assessment Pathway Prostate Biopsy Alerts Prostate Assessment Pathway Prostate Biopsy Alerts Guidelines for the Management of Patient Preparation, Medications and Complications July 2015 Table of Contents Roles and Responsibilities. 1 SECTION

More information

New Oral Anticoagulants

New Oral Anticoagulants New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.

More information

Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center

Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will

More information

Disclosures. New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century

Disclosures. New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University

More information

Anticoagulant therapy

Anticoagulant therapy Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in

More information

3/3/2015. Patrick Cobb, MD, FACP March 2015

3/3/2015. Patrick Cobb, MD, FACP March 2015 Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict

More information

Clinical Guideline N/A. November 2013

Clinical Guideline N/A. November 2013 State if the document is a Trust Policy/Procedure or a Clinical Guideline Clinical Guideline Document Title: Document Number 352 Version Number 1 Name and date and version number of previous document (if

More information

Anticoagulation in Atrial Fibrillation

Anticoagulation in Atrial Fibrillation Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis

More information

Investor News. Not intended for U.S. and UK media

Investor News. Not intended for U.S. and UK media Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism

More information

Anticoagulation and Reversal

Anticoagulation and Reversal Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,

More information

Goals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD

Goals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs

More information

New Anticoagulants: When and Why Should I Use Them? Disclosures

New Anticoagulants: When and Why Should I Use Them? Disclosures Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia

More information

2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.

2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2. Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order

More information

Updates to the Alberta Drug Benefit List. Effective January 1, 2016

Updates to the Alberta Drug Benefit List. Effective January 1, 2016 Updates to the Alberta Drug Benefit List Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)

More information

EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation

EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention

More information

Anticoagulation For Atrial Fibrillation

Anticoagulation For Atrial Fibrillation Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator

More information